OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial For …

OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial For …

Once an optimal combination dose is established, three expansion study cohorts will be enrolled in non-small cell lung cancer (NSCLC), anti-PD1 refractory solid tumors and castrate-resistant prostate cancer. … To the extent that statements contained

(Visited 1 times, 1 visits today)
4
Like
Save

Comments

Comments are disabled for this post.